Key result
STEMI with cardiogenic shock linked to 35.5% in-hospital mortality and less primary PCI.
Why the study?
To determine the current use of reperfusion and adjunctive therapies and in-hospital outcomes across ESC member and affiliated countries for patients with STEMI complicated by cardiogenic shock.
What is the current state of reperfusion therapy use and in-hospital outcomes for patients with STEMI complicated by cardiogenic shock?
Cohort (n=11,462)
Yes
What is the current state of reperfusion therapy use and in-hospital outcomes for patients with STEMI complicated by cardiogenic shock?
Patients with STEMI complicated by cardiogenic shock receive reperfusion therapy less frequently than those without shock, and experience very high early mortality, especially when not treated with primary PCI.
Answers are grounded in this paper and cite their sources.
STEMI with cardiogenic shock shows high mortality and lower primary PCI rates; leaves open whether increasing reperfusion improves survival.
AIMS: To determine the current state of the use of reperfusion and adjunctive therapies and in-hospital outcomes in European Society of Cardiology (ESC) member and affiliated countries for patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS). METHODS AND RESULTS: ESC EurObservational Research Programme prospective international cohort study of admissions with STEMI within 24 h of symptom onset (196 centres; 26 ESC member and 3 affiliated countries). Of 11 462 patients enrolled, 448 (3.9%) had CS. Patients with compared to patients without CS, less frequently received primary percutaneous coronary intervention (PCI) (65.5% vs. 72.2%) and fibrinolysis (15.9% vs. 19.0), and more often had no reperfusion therapy (19.0% vs. 8.5%). Mechanical support devices (intraaortic ballon pump 11.2%, extracoporeal membrane oxygenation 0.7%, other 1.1%) were used infrequently in CS. Bleeding definition academic research consortium 2-5 bleeding complications (10.1% vs. 3.0%, P < 0.01) and stroke (4.2% vs. 0.9%, P < 0.01) occurred more frequently in patients with CS. In-hospital mortality was 10-fold higher (35.5% vs. 3.1%) in patients with CS. Mortality in patients with CS in the groups with PCI, fibrinolysis, and no reperfusion therapy were 27.4%, 36.6%, and 62.4%, respectively. CONCLUSION: In this multi-national registry, patients with STEMI complicated by CS less frequently receive reperfusion therapy than patients with STEMI without CS. Early mortality in patients with CS not treated with primary PCI is very high. Therefore, strategies to improve clinical outcome in STEMI with CS are needed.
No takes yet. Share an insight, caveat, or question.
Zeymer et al. (2022) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS) (n=11,462). Cardiogenic shock vs. No cardiogenic shock was evaluated on In-hospital mortality. STEMI complicated by cardiogenic shock was associated with higher in-hospital mortality and lower rates of primary PCI compared to STEMI without shock.
Synapse has enriched 10 related papers. Consider them for comparative context: